Page 4 - பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா கீந் சிகிச்சை ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா கீந் சிகிச்சை ப்ரோக்ர்யாம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா கீந் சிகிச்சை ப்ரோக்ர்யாம் Today - Breaking & Trending Today

Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25

Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25
PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced it will host a series of virtual Research & Development events in 2021, with the first one scheduled for Monday, January 25, 2021, 11 a.m. to 1 p.m. ET.
The first event will focus on Passage Bio’s lead investigational therapy PBGM01 and its disease target, infantile GM1 gangliosidosis (GM1). Presenters for the event are:
Bruce Goldsmith, Ph.D., chief executive officer, who will present an overview of the Passage Bio pipeline and the GM1 disease and patient experience. ....

United States , University Of Pennsylvania , Gwen Fisher , Jamesm Wilson , Christian Hinderer , Bruce Goldsmith , Sarah Mccabe , Zofia Mita , Gary Romano , Stern Investor Relations Inc , University Of Pennsylvania Gene Therapy Program , European Commission , Passage Bio Inc , Research Development , Gene Therapy Program , Exchange Commission , University Of Pennsylvania Penn , Passage Bio , Orphan Drug Designations , Rare Pediatric Disease Designation , Private Securities Litigation Reform Act , Risk Factors , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா , க்வென் மீனவர் ,

Passage Bio Announces Gene Therapy Manufacturing Research and Development Site

Published: Dec 16, 2020
PHILADELPHIA, Dec. 16, 2020 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced that it has entered into a long-term lease to support Chemistry, Manufacturing and Controls (CMC) laboratory operations for the company’s gene therapy programs. The new laboratory, slated to open in the second quarter of 2021 at the Princeton West Innovation Campus in Hopewell, New Jersey, will initially focus on state-of-the-art analytical capabilities, clinical assay development and validation, biomarker assay validation and clinical product testing to support both viral vector manufacturing and clinical development. ....

University Of Pennsylvania , United States , New Jersey , Gwen Fisher , Bruce Goldsmith , Sarah Mccabe , Zofia Mita , Alex Fotopoulos , Exchange Commission , Stern Investor Relations Inc , University Of Pennsylvania Gene Therapy Program , Passage Bio Inc , Upenn Gene Therapy Program , Princeton West Innovation Campus , Passage Bio , Gene Therapy Program , Private Securities Litigation Reform Act , Risk Factors , Bio Investors , Investor Relations , Bio Media , பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா , ஒன்றுபட்டது மாநிலங்களில் , புதியது ஜெர்சி , க்வென் மீனவர் , காயங்கள் பொற்கொல்லர் ,

Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis

- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program - - Patient enrollment in UK clinical study site expected to start in the second quarter of 2021 - ....

United States , University Of Pennsylvania , United Kingdom , Gwen Fisher , James Wilson , Bruce Goldsmith , Sarah Mccabe , Zofia Mita , Gary Romano , Stern Investor Relations Inc , University Of Pennsylvania Gene Therapy Program , European Commission , Passage Bio Inc , Gene Therapy Program , Exchange Commission , University Of Pennsylvania Penn , Medicines Healthcare Products Regulatory Agency , Clinical Trial Authorization , Passage Bio , Orphan Drug Designations , Rare Pediatric Disease Designation , Private Securities Litigation Reform Act , Risk Factors , Bio Investors , Investor Relations , Bio Media ,